Search Results

Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”) announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.

Galmed Pharmaceuticals Ltd. reported the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments

Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

Galmed Pharmaceuticals Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

Galmed Pharmaceuticals Ltd. announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the “Offering”).

Galmed Pharmaceuticals Ltd. is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed’s innovative Primary Sclerosing Cholangitis (PSC) clinical development program.

Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission.